Pavunalimab Biosimilar – Anti-LAG3;CTLA4 mAb – Research Grade

Pavunalimab Biosimilar: A Promising Antibody for Targeting LAG3 and CTLA4 Introduction

Pavunalimab Biosimilar, also known as Anti-LAG3,CTLA4 mAb, is a novel therapeutic antibody that has shown promising results in preclinical studies for the treatment of various diseases. This biosimilar is designed to target two important immune checkpoints, LAG3 and CTLA4, which play crucial roles in regulating the immune response. In this article, we will provide a scientific description of the structure, activity, and potential applications of Pavunalimab Biosimilar.

Structure of Pavunalimab Biosimilar

Pavunalimab Biosimilar is a monoclonal antibody (mAb) that is produced by recombinant DNA technology. It is a fully human IgG1 antibody, meaning that it is derived from human cells and has a structure similar to naturally occurring antibodies in the body. The antibody consists of two heavy chains and two light chains, each with specific binding sites for LAG3 and CTLA4.

Activity of Pavunalimab Biosimilar

Pavunalimab Biosimilar is designed to target two immune checkpoints, LAG3 and CTLA4, which are expressed on the surface of immune cells. These checkpoints play important roles in regulating the immune response and preventing excessive activation of immune cells. However, in certain diseases, these checkpoints can be overexpressed, leading to immune dysfunction. Pavunalimab Biosimilar works by binding to LAG3 and CTLA4, blocking their activity and restoring the balance of the immune system.

Potential Applications of Pavunalimab Biosimilar

Pavunalimab Biosimilar has shown promising results in preclinical studies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. As LAG3 and CTLA4 are involved in regulating the immune response, targeting these checkpoints with Pavunalimab Biosimilar can potentially enhance the anti-tumor immune response and improve the efficacy of cancer immunotherapy. In addition, the antibody has shown potential in treating autoimmune disorders such as rheumatoid arthritis and multiple sclerosis, as well as infectious diseases such as HIV and hepatitis B.

Advantages of Pavunalimab Biosimilar

Pavunalimab Biosimilar has several advantages over existing therapies targeting LAG3 and CTLA4. As a fully human antibody, it has a lower risk of immune reactions and is less likely to cause adverse effects. In addition, the biosimilar has a longer half-life, allowing for less frequent dosing and potentially improving patient compliance. Moreover, as a biosimilar, it is expected to have a lower cost compared to the originator drug, making it more accessible to patients.

Conclusion

In summary, Pavunalimab Biosimilar is a promising therapeutic antibody that targets two important immune checkpoints, LAG3 and CTLA4. Its unique structure and mechanism of action make it a potential treatment option for various diseases, including cancer, autoimmune disorders, and infectious diseases. With its advantages over existing therapies, Pavunalimab Biosimilar has the potential to improve patient outcomes and make a significant impact in the field of immunotherapy.

ProteoGenix catalogue number PX-TA1699. For research use only.

Target: Pavunalimab Biosimilar – Anti-LAG3;CTLA4 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet